Hemanext - Safer Transfusions, Healthier Patients

Our Mission

Safer Transfusions, Healthier Patients.
That’s Our Mission.

News & Events

Hemanext^® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System

Company to launch red blood cell (RBC) processing and storage system in select European markets in 2021, with wider distribution in Europe and the Americas in 2022 and future years.

Sickle Cell Disease Association of America, Inc. Launches New Educational Materials to Support Children’s Blood Transfusion

Sickle Cell Disease Association of America, Inc. (SCDAA) and Hemanext Inc., today announced the launch of new educational material to help SCDAA deliver on its mission and meet its goals.

INVESTORS

Current and prospective investors access to the investor Portal

COVID 19 Updates

Follow the course of COVID-19 and locate where to donate blood

Educational Symposiums

View educational material and interesting presentations

Our Science

Learn about the journey of red blood cells after donation including degradation that occurs during storage and discover the potential of hypoxic storage to alleviate this problem.

Stored Blood

The average human body stores about 5.6 liters of blood. As it circulates through the body several times each minute, it accomplishes a variety of functions.

Storage Lesion

The existence of the storage lesion process has been well established, and recent scientific work has increased the precision and depth.

Numerous studies pertaining to clinical implications of storage lesion suggest a linkage to hyper-coagulability, inflammation, impaired perfusion, immuno-modulation, organ dysfunction¹³, and mortality¹⁴.

Hypoxic Storage

Hemanext is developing a technology to enable the storage of RBC under hypoxic conditions. Removing O2 during storage removes the primary “fuel” for oxidative stress1-11.

Hemanext Research

Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.

Worldwide Patent Assets

Accepted Scientific Abstracts

Total Publications

Our Technology

Hemanext ONE^®

The Hemanext ONE^® system enables processing and storage of oxygen and carbon dioxide reduced red blood cells. Our system seeks to provide a more consistent and higher red blood cell (RBC) by removing the fuel for oxidative damage.

Learn More

CONNECT WITH HEMANEXT TODAY TO LEARN MORE!

We are happy to answer any questions about the company, our technology, or our research. Fill out the form below and we will connect with you!

YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE

Safer Transfusions, Healthier Patients.That’s Our Mission.